Research Interests
Urologic and Sexual Health Manifestations of Spina Bifida
Selected Grants
Duke KURe Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2013 - 2028Kangaroo - A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of
Clinical TrialPrincipal Investigator · Awarded by Urovant Sciences · 2022 - 2025National Spina Bifida Patient Registry and Urologic Management of Young Children with Spina Bifida - Component B
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2019 - 2025Urologic Management to Preserve Renal Function Protocol - Component C
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2019 - 2025An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 3 to less than 18 Years of Age
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Inc. · 2018 - 2020Duke KURe Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2013 - 2028Kangaroo - A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of
Clinical TrialPrincipal Investigator · Awarded by Urovant Sciences · 2022 - 2025National Spina Bifida Patient Registry and Urologic Management of Young Children with Spina Bifida - Component B
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2019 - 2025Urologic Management to Preserve Renal Function Protocol - Component C
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2019 - 2025An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 3 to less than 18 Years of Age
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Inc. · 2018 - 2020Comp C -Urologic Management to Preserve Renal Function Protocol - Duke Project
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2014 - 2019Comp B - National Spina Bifida Patient Registry and Urologic Management of Young Children with Spina Bifida - Duke Project
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2014 - 2019IDENTIFICATION OF VUR GENES BY COMBINED LINKAGE ANALYSIS AND EXOME SEQUENCING
ResearchCollaborator · Awarded by National Institutes of Health · 2013 - 2015National Spina Bifida Patient Registry - Duke Clinic Demonstration Project
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2011 - 2014External Relationships
- Expert Witness / Case Review
- Spina Bifida Association
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.